Tranylcypromine (2-PCPA) is an irreversible inhibitor of LSD1 histone demethylase and monoamine oxidases (MAO). The inhibitor targets monoamine oxidases A and B and has been used as a chemical scaffold to design new demethylase inhibitors. Tranylcypromine has been shown to increase Histone H3 lysine 4 (H3K4) methylation in P19 embryonal carcinoma cell.

≥98% by HPLC

Tranylcypromine inhibits LSD1 with an IC50 value of 20.7 µM and a Ki value of 242.7 µM. It also irreversibly inhibits MAO A and MAO B with IC50 values of 2.3 and 0.95 µM and Ki values of 101.9 and 16 µM, respectively.

Soluble in water (25 mg/ml).

A white to off white solid

Store solid form at +4°C. Hygroscopic. Solid form is stable at least 12 months from date of receipt, when stored as directed. Aqueous solutions are less stable; we recommend preparing and using stock solutions the same day.

1. Schmidt, D.M.Z., and McCafferty, D.G. et al. Biochemistry 46:4408-4416 (2007)
2. Yang, M., et al. Biochemistry 46:8058-65(2007)

Application Reference(s):
The lysine demethylase LSD1 is required for nuclear envelope formation at the end of mitosis (2015)

Hygroscopic. Protect from moisture. Protect from light.

Demethylase

Inhibitor